Oct 26 (Reuters) - Trinity Biotech PLC :Trinity biotech announces results for Q3, 2017.Q3 earnings per share $0.063.Q3 revenue $25.6 million versus I/B/E/S view $26.1 million.
Full Article
July 20 (Reuters) - Trinity Biotech Plc ::Trinity Biotech announces results for Q2, 2017.Q2 earnings per share $0.068.Q2 revenue $25.4 million versus I/B/E/S view $25.5 million.Q2 earnings per share $0.031 excluding items.
Full Article
April 27 (Reuters) - Trinity Biotech Plc :Trinity biotech announces results for q1, 2017.Q1 earnings per share $0.05.Q1 revenue $23.5 million.Q1 revenue view $24.3 million -- Thomson Reuters I/B/E/S.
Full Article
Trinity Biotech Plc :Lapides Asset Management LLC reports 5.1 percent passive stake in trinity Biotech Plc as of March 6 - sec filing.
Full Article
Trinity Biotech Plc : Trinity biotech announces quarter 4 and fiscal year 2016 financial results . Quarterly earnings per share $0.043 . Q4 revenue $23.7 million versus i/b/e/s view $25.8 million . Trinity biotech plc - during quarter company recognised once-off charges amounting to $105.8 million net of tax .Trinity biotech plc - with closure of our swedish facility, going forward we will operate at close to a free cash flow break even position.
Full Article
Trinity Biotech Plc : Trinity biotech announces withdrawal of Troponin FDA 510(k) submission . FDA asked trinity to consider withdrawing their submission, due to some concerns they have about submission . To move technology from swedish facility to facility in ireland where it will be incorporated into research and development,manufacturing infrastructure . Moving of technology will result in closure of uppsala facility in sweden, which will result in approximately 40 redundancies . Trinity biotech announces withdrawal of troponin fda 510(k) submission . Held a meeting with fda on thursday 29 september, in order to obtain an update on company's meritas troponin submission . Fda asked trinity to consider withdrawing their submission, due to some concerns they have about submission . Fda's primary concerns relate to device's operating temperature range . "over coming weeks we will engage with fda to gain a better understanding of nature of their concerns" . Fda concerns also relate to troponin-i clinical performance not being consistent with clinical performance data .Will also recognise a non-cash write-off in excess of $50m, representing costs incurred on project, which will be recognised in q4.
Full Article
Earnings vs. 
Estimates